Compass Therapeutics, Inc. - Common Stock (CMPX)

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.

CMPX stock results show that Compass Therapeutics met analyst estimates for earnings per share the second quarter of 2024.

CMPX stock results show that Compass Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

The 10X penny stocks discussed here are a much more reliable investment than many other alternatives investors are likely to encounter.

CMPX stock results show that Compass Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

These are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation.

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) rose 65.3% to $12.20 in pre-market trading after gaining around 9% on Friday.